Charles River Laboratories International, Inc. (NYSE:CRL) Receives $255.65 Consensus Price Target from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has earned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $255.6471.

CRL has been the topic of several research reports. Robert W. Baird set a $291.00 price target on shares of Charles River Laboratories International in a research report on Thursday, August 6th. Barclays reaffirmed an “overweight” rating and issued a $300.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, August 5th. TD Cowen boosted their target price on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a report on Monday, August 10th. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st.

Insider Buying and Selling at Charles River Laboratories International

In other news, CAO Michael Gunnar Knell sold 6,645 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $260.38, for a total value of $1,730,225.10. Following the sale, the chief accounting officer directly owned 11,852 shares of the company’s stock, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 129,817 shares of company stock worth $31,774,935. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Invesco Ltd. increased its holdings in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Charles River Laboratories International during the fourth quarter valued at $176,478,000. Victory Capital Management Inc. grew its position in Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after buying an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after acquiring an additional 575,039 shares in the last quarter. Finally, Amundi raised its holdings in shares of Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $279.70 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The stock has a fifty day simple moving average of $224.87 and a two-hundred day simple moving average of $191.33. Charles River Laboratories International has a 1-year low of $144.26 and a 1-year high of $288.02. The firm has a market cap of $13.35 billion, a price-to-earnings ratio of -57.67, a price-to-earnings-growth ratio of 2.90 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts anticipate that Charles River Laboratories International will post 11.35 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.